From: A Review of the Adverse Effects of Peripheral Alpha-1 Antagonists in Hypertension Therapy
Study | Number of subjects | Type of Study | Weight change in kilograms (number on therapy) | |||
---|---|---|---|---|---|---|
Doxazosin | Placebo | Other therapy | p-value¶ | |||
Ames [30] | 147 | RCT | +1.5 (n = 73) | -0.2 kg (n = 74) | 'significant' | |
ABC trial [31]* | 191 | RCT | + 1.16 (n = 96) | -0.04, atenolol (n = 95) | p = .019 | |
Ott [32] | 126 | RCT | +2.0 (n = 63) | + 0.9, atenolol (n = 63) | NS | |
Torvik [33] | 172 | RCT | + 0.04 ± 0.2 (n = 58) | -1.18 ± 0.29 (n = 57) | +0.21 ± 0.2, prazosin (n = 57) | p < .001 for treated groups |
TOMHS [34]† | 902 | RCT | -3.1 (n = 134) | -3.9, chlorthalidone (n = 136) | NS |